Skip to main content

Advertisement

SpringerLink
Log in

Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Individual differences in cytochrome P-450 efficiency partly explain their variations in resistance to tamoxifen and estrogen metabolism. Two polymorphisms of the CYP1A1 gene—A4889G and T6235C—are known to affect activation of estrone and estradiol and to deregulate concentration of highly active tamoxifen metabolites. However, the clinicopathologic implications of these findings have not yet been evaluated.

Objective

The objective of this study is to evaluate whether T6235C and A4889G gene polymorphisms are related to pathological presentations and clinical outcomes of ER+/PR+ breast cancer (BC) in women using tamoxifen.

Methods

We included 405 women with ER+/PR+ tumors, who used tamoxifen as their primary therapy, and for whom 5-year follow-up data were available. We evaluated associations within clinicopathologic features, including overall 5-year survival, with CYP1A1 gene status.

Results

Univariate analysis showed that a slightly higher proportion of women with AG/GG genotypes were of European descent (P = 0.05) and that TC/CC genotype was significantly associated with premenopausal status (P = 0.01); however, no significant association remained after multivariate adjustment. Women with CYP1A1 genotypes other than AA and TT were more prone to develop low-grade tumors; 85.9 % of tumors in AA and TT genotype groups were grade III, but only 76.1 % of tumors in carriers of the polymorphisms were grade III (adjusted P = 0.02; OR 0.51 for grade III disease; 95 % CI 0.28–0.93). After 60 months of follow-up, ~75 % of the women were alive. There was no significant difference in survival related to the CYP1A1 gene status.

Conclusions

Breast cancer patients carrying CYP1A1 gene polymorphisms developed less aggressive tumors, but showed no evidence of better prognoses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Stearns V, Johnson MD, Rae JM et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764

    Article  CAS  Google Scholar 

  2. Johnson MD, Zuo H, Lee KH et al (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151–159

    Article  CAS  Google Scholar 

  3. Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471–478

    Article  CAS  Google Scholar 

  4. MacCallum J, Cummings J, Dixon JM, Miller WR (2000) Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer 82:1629–1635

    Article  CAS  Google Scholar 

  5. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A et al (2004) Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10:2336–2343

    Article  CAS  Google Scholar 

  6. Sharma M, Shubert DE, Sharma M et al (2003) Biotransformation of tamoxifen in a human endometrial explant culture model. Chem Biol Interact 146:237–249

    Article  CAS  Google Scholar 

  7. Parte P, Kupfer D (2005) Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos 33:1446–1452

    Article  CAS  Google Scholar 

  8. van Schaik RH (2008) CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 11:77–98

    Article  Google Scholar 

  9. Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062–1075

    Article  CAS  Google Scholar 

  10. Sun D, Sharma AK, Dellinger RW et al (2007) Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 35:2006–2014

    Article  CAS  Google Scholar 

  11. Nishiyama T, Ogura K, Nakano H et al (2002) Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817–1830

    Article  CAS  Google Scholar 

  12. Nowell S, Falany CN (2006) Pharmacogenetics of human cytosolic sulfotransferases. Oncogene 25:1673–1678

    Article  CAS  Google Scholar 

  13. Seruga B, Amir E (2010) Cytochrome P450 2D6 and outcomes of adjuvante tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat 122(3):609–617

    Article  CAS  Google Scholar 

  14. Abrahan JE, Maranian MJ, Driver KE et al (2010) CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 12(4):R64

    Article  Google Scholar 

  15. Parl FF, Dawling S, Roodi N, Crooke PS (2009) Estrogen metabolism and breast cancer: a risk model. Ann NY Acad Sci 1155:68–75

    Article  CAS  Google Scholar 

  16. Tsuchiya Y, Nakajima M, Yokoi T (2005) Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 227:115–124

    Article  CAS  Google Scholar 

  17. Oliveira C, Lourenço GJ, Silva PM et al (2011) Polymorphisms in the 5′- and 3′-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics. Tumour Biol 32:295–300

    Article  CAS  Google Scholar 

  18. Cardoso-Filho C, Lourenço GJ, Shinzato JY, Zeferino LC, Costa FF (2008) Clinical and pathological implications of GSTM1 and GSTT1 gene deletions in sporadic breast cancer. Oncol Rev 2:36–43

    Article  Google Scholar 

  19. Woodhead JL, Fallon R, Figuered H, Longdale J, Malcom AD (1986) Alternative methodology of gene diagnosis. In: Davies KE (ed) Human genetic diseases: a practical approach. IRL Press, Oxford, pp 51–64

    Google Scholar 

  20. Canalle R, Burim RV, Tone LG, Takahashi CS (2004) Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Environ Mol Mutagen 43:100–109

    Article  CAS  Google Scholar 

  21. Wang J, Deng Y, Li L et al (2003) Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocarcinoma: a case-control study in Chinese population. Cancer Sci 94:448–452

    Article  CAS  Google Scholar 

  22. Joseph T, Kusumakumary P, Chacko P, Abraham A, Radhakrishna Pillai M (2004) Genetic polymorphisms of CYP1A1, CYP2D6, GSTM1, GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer 43:560–567

    Article  Google Scholar 

  23. Schneider J, Huh MM, Bradlow LH, Fishman J (1984) Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 259:4840–4845

    CAS  Google Scholar 

  24. Fotsis T, Zhang Y, Pepper MS et al (1994) Endogenous estrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368:237–239

    Article  CAS  Google Scholar 

  25. Cushman M, He HM, Katzenellenbogan JA, Lin CM, Hamel E (1995) Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 38:2041–2049

    Article  CAS  Google Scholar 

  26. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchió C, Reis-Filho JS (2010) Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 57(2):171–192

    Article  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Campinas State University, Campinas, São Paulo, Brazil

    Cassio Cardoso-Filho, Luis Otavio Sarian, Leonardo da Silveira Bossi & Maria Salete Costa Gurgel

  2. Department of Internal Medicine, Campinas State University, Campinas, São Paulo, Brazil

    Camila Borges Martins de Oliveira, Gustavo Jacob Lourenço & Carmen Silvia Passos Lima

Authors
  1. Cassio Cardoso-Filho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis Otavio Sarian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Camila Borges Martins de Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Leonardo da Silveira Bossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gustavo Jacob Lourenço
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carmen Silvia Passos Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Salete Costa Gurgel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cassio Cardoso-Filho.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cardoso-Filho, C., Sarian, L.O., de Oliveira, C.B.M. et al. Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival. Cancer Chemother Pharmacol 72, 529–535 (2013). https://doi.org/10.1007/s00280-013-2221-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-013-2221-y

Keywords

Search

Navigation